A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

NCT07441460 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1800

Enrollment

INDUSTRY

Sponsor class

Conditions

Resectable HER2-positive Breast Cancer

Interventions

DRUG: KN026
DRUG: HB1801
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Docetaxel
DRUG: Epirubicin
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Carboplatin

Sponsor

Shanghai JMT-Bio Inc.